Source: Eur Respir J, 56 (3) 2002510; 10.1183/13993003.02510-2020
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jan-Willem C. Alffenaar, Simon Tiberi, Daniela M. Cirillo, Giovanni Battista Migliori. Intermittent regimens for tuberculosis treatment: Back to the Future?. Eur Respir J, 56 (3) 2002510; 10.1183/13993003.02510-2020

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 Future treatment modalities Source: ERS Course 2016 Year: 2016 Future treatment for asthma Source: Eur Respir Rev 2015; 25: 77-92 Year: 2016 Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011 Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 Pharmacological options for the treatment of COPD: present and future Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy Year: 2007 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Prevalence of inappropriate tuberculosis treatment regimens: a systematic review Source: Eur Respir J 2012; 39: 1012-1020 Year: 2012 Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Therapeutic strategies: what treatment for what patient Source: Annual Congress 2008 - PG12 - Challenges in pulmonary embolism: hot issues and interactive cases (jointly organised with ACCP) Year: 2008 Response to pulmonary rehabilitation: toward personalised programmes? Source: Eur Respir J 2015; 46: 1538-1540 Year: 2015 Four-month regimens: are they feasible? Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 New short regimens for latent tuberculosis treatment: safety first! Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018 Year: 2018 Treatment of patients with extensive TB and concomitant bronchial lesions with some anti-TB drugs delivered via nebulizer Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013